compel product pipelin eras broader
challeng gener drug industri
updat forecast estim
conduct analyst
govern code ethics/cod conduct
polici secur trade polici
equival invest research
interest visit
primari analyst cover compani
stock
research
estim
price data
rate updat
currenc amount express
valuat growth profit
methodolog valu compani
may becom largest gener drug manufactur
year thank on-going acquisit compel gener
restasi regardless still long-term concern
hefti price pressur gener industri firm high
capit larg valu drug come patent
past year see increas challeng ahead
think recent sluggish industri growth continu due fewer
larg drug patent expir consolid custom base
unit state entri nimbl low-cost competitor
acquisit agila meda abbott non-u
increas product
geograph diversif competit dynam
govern price continu limit organ growth
opportun europ well
follow similar strategi peer intend overcom
gener industri concern expand specialti pharma
complex gener oper complex gener
biosimilar inject respiratori inhal gener face
limit competit enjoy higher margin thank higher
develop manufactur regulatori hurdl
develop biosimilar gener insulin partner biocon
momenta among attempt gener version
glaxosmithklin advair despit recent gener copaxon
approv still skeptic success
complex product think compani trail
peer biosimilar
specialti drug segment made primarili epipen
grown expect emerg compet
epinephrin product pressur segment futur growth
profit follow recent critic price increas
manag launch author epipen gener late
see potenti gener launch teva beyond
epipen compani mostli lack pipelin brand drug
valuat summari forecast
financi summari forecast
historical/forecast data sourc morningstar estim may reflect adjust
one world largest gener pharmaceut manufactur
oper unit state europ asia middl east africa
australia gener drug sale constitut approxim revenu
remain sale come hand brand product primarili
epinephrin injector epipen also own matrix indian activ
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
valuat growth profit
rais fair valu estim per share
make slight posit adjust
revenu margin forecast firm fair valu
approxim reflect compani growth
challeng gener drug industri epipen
sale growth gener segment
european market growth imagin gener
sale remain slow larg expir
growth specialti segment larg driven increas
sale epipen stall follow potenti
gener launch teva forecast also includ
contribut probability-weight gener advair
revenu lead stronger growth although
advanc biosimilar product clinic
trial made us optimist approv
product remain somewhat skeptic complex
biosimilar like humira addit gener insulin
product like lantu forese potenti biosimilar
revenu
greater economi scale realiz acquisit
synergi potenti launch specialti product like
gener advair help off-set competit pressur
epipen keep profit rel stabl near term
model long-term margin compress epipen
sale erod aggress competit gener
industri persist also project tax rate
high teen thank tax invers acquir
abbott asset on-going intern expans
recent tax legisl forecast oper
margin near result return capit
approach peg compani cost capit
give mylan high uncertainti rate due
rel high geograph product concentr
addit pipelin unpredict gener
product includ gener form advair lantu
biosimilar better-than-expect success number
complex product launch could caus
outperform expect howev
bull-cas scenario model low-double-digit growth
asia-pacif revenu mid-single-digit growth north
american european revenu lead organ
five-year compound growth rate gener
product revenu growth less-competit market share
loss price pressur epipen combin faster
market share gain biosimilar respiratori
pressur patent cliff greater biosimilar
launch success achiev
better-than-expect restructur effort manufactur
scale forecast oper margin near
bull-cas scenario result fair valu estim
bear-cas scenario gener segment forecast
incorpor greater price eros market along
low- mid-single-digit growth european
steeper market-shar loss epipen addit lower
market-shar gain biosimilar respiratori
inhal insulin along nearli flat revenu
growth project price pressur lead oper
margin near bear-cas scenario share
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
gener product includ version advair
insulin biosimilar despit recent success
copaxon remain skeptic success
product given high manufactur regulatori
hurdl even receiv approv biosimilar
like need hefti market effort product
sinc lack bioequival mean look less
well posit adept biopharma firm enter
space particularli novarti
mylan specialti drug franchis also benefit patent
protect drive consider profit key
franchis essenti compos entir epipen
creat sustain competit advantag due
compani heavi concentr product epipen still
repres larg portion busi
sale profit estim although epipen
may face limit gener competit teva
addit author gener thank manufactur
complex brand recognit uniqu product
still imagin price pressur depress drug
momentum meanwhil major brand
product pipelin
think neg econom moat trend
think rel larg exposur
europ gener drug market threaten erod firm
cost advantag time addit upcom gener
competit epipen diminish price power
also skeptic eventu success certain
pipelin product includ biosimilar gener
advair develop success launch
product could caus us re-evalu long-term
assumpt
think possess econom moat
consid gener drug industri whole
predominantli no-moat industri barrier entri remain
low product remain highli commodit industri
previous thought global economi scale
vertic integr help give firm low-cost edg
think continu rise new entrant particularli
low-cost emerg market continu diminish cost
advantag larger peer addit believ
mylan first-to-fil pipelin manufactur capabl
complex product help differenti firm
heavili commodit aspect
industri diminish confid lead
sustain econom profit long term
abil challeng gradual improv lack larg
number product go patent increas gener
util rate seen last decad probabl mean
growth margin expans firm past
difficult sustain go forward
possess fairli larg pipelin complex
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
one world largest gener industri player
enjoy economi scale smaller
ocompar peer less diversifi
oper increas exposur volatil gener
oth acquisit agila meda boost
inject over-the-counter drug product
sustain steadier growth profit thank
limit competit market segment
face consider competit low-cost
develop complex gener drug
includ biosimilar gener version advair
copaxon
earn growth approv
possibl gener version teva
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
equival begin period
total avail debt servic
oblig commit
total oblig commit
adjust free
gener
gener revolv adjust
commit
appetit acquisit drive growth prospect
probabl keep financi leverag rel high mylan
use consider debt purchas matrix merck
kgaa gener subsidiari respect
result compani financi leverag although
manag stood consider higher
gener competitor manag done good job
year boost growth profit
help eas debt repay concern moreov
all-stock acquisit abbott non-u developed-market
asset help de-lever compani
purchas meda late increas financi
leverag end net debt/ebitda ratio
approxim time could declin
thank recent gener copaxon launch
potenti product approv regardless think
level debt repres realist long-term averag given
compani acquisit appetit
histori aggress acquisit
diversifi oper pipelin uncertain product
like gener advair insulin make higher-risk
oper peer view mylan
sizabl global footprint still consider
exposur gener drug market
eventu declin valu drug come patent could
spell troubl addit even close abbott
meda deal signific portion oper
remain center western europ face stiff
price pressur year also lack sizabl
brand drug segment innov pipelin
possess epipen franchis drug face potenti
gener competit teva addit recent
critic price increas epipen spur
manag offer access program author
gener diminish near-term sale
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
manag also settl depart
justic million critic epipen
classif gener product medicaid rebat
program bold pipelin complex gener product
includ copaxon advair biosimilar insulin could
eventu off-set competit epipen think
uncertainti approv product remain high
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
repres date owner name posit common share held report holder issuer
share
fund
share
fund
think averag stewardship practic
effect capit alloc mix view
mani manag strateg initi past
year bolster compani oper
includ scale vertic integr manufactur
capabl hard-to-manufactur product howev
think high take-over multipl larg amount financi
leverag slow integr process acquir
busi hamper potenti sharehold return
declin high geograph concentr
southern region contin
particularli affect auster measur although mylan
gain greater diversif scale lower tax rate
acquisit abbott developed-market asset
follow recent purchas meda still
concern growth prospect europ
follow deal addit high-stak
acquisit inject manufactur agila becam
cloud compani receiv food drug
administr warn letter manufactur
qualiti concern recent critic price increas
epipen led neg media attent settlement
 depart justic improp
classif drug medicaid rebat program
compar peer consid execut pay
significantli averag includ person aircraft
use company-provid automobil larg portion
execut compens tie adjust earn per
share good measur long-term valu
creation view also skeptic manag
aggress long-term guidanc either assum
approv compani complex pipelin
product take optimist acquisit outlook
heather bresch compani nearli
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
year becam ceo earli robert couri
ceo sinc transit execut chairman
bresch couri presid rajiv malik repres three
compani insid board multist civil
investig potenti price collus among gener
manufactur recent target malik mark
parrish replac rodney piatt lead independ director
vice chairman board parrish board
member sinc current chairman ceo
trident provid mobil x-ray laboratori servic
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
outlook expect
although make adjust model
dont plan chang fair valu estim
compani fourth-quart result outlook
mostli match expect forecast billion
revenu adjust ep year fall
near midpoint manag guidanc
notch recent gener copaxon mg approv
continu compel gener product
pipelin includ potenti approv gener
advair gener restasi summer regardless
leav no-moat rate unchang given tough
competit environ global gener industri
mylan diversifi geograph footprint complex
product pipelin includ biosimilar help
compani off-set broader competit pressur
gener market epipen franchis north american
sale year-ago period
manag outlook incorpor roughli flat sale
region roughli line
expect manag note price pressur
 market remain high-single-digit rang
expect continu year well
regardless grow mix limit competit
product like gener copaxon help lift firm
intern oper remain area rel stabil
time
manag announc partnership revanc
develop botox biosimilar pend detail think
remain hard compani match allergan
product familiar market reach aesthet
therapeut indic neither compani materi
expertis exposur wide array specialist
botox market varieti indic
trail exist botox biosimilar like dysport xeomin
face limit market share gain
end perform track
although third-quart result continu reflect
pressur epipen gener busi
declin revenu declin adjust ep
launch gener copaxon dramat improv
year-end result gener version
market share new copaxon prescript late
octob result compani perform remain
line expect year-end adjust ep
estim midpoint manag
updat outlook leav fair valu estim
no-moat rate place compel
product launch opportun pipelin continu
think low barrier entri gener drug industri
remain tough environ build moat long
although futur perform remain tie
uncertain gener launch like restasi advair
adjust ep target seem achiev howev
uncertain time momenta partner novarti
gener copaxon approv well teva pend
bump exclud declin epipen north american
sale fell year ago manag note high-
single-digit price eros base gener busi
combin loss exclus certain product
came line project outlook
applic approv fda consolid
benefici currenc effect revenu meda
acquisit sale outsid climb low-single-
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
digit calcul meet expect
lastli paid roughli half epipen medicaid
settlement quarter remaind
end year
execut expand gener
multist civil investig potenti price collus
among gener manufactur expand number
compani drug examin
particularli surpris see investig broaden --
includ firm like novarti actavi part teva
dr reddi laboratori endo --
specif target presid execut
director rajiv malik may potenti expos
compani greater scrutini
on-going ambigu extent wrongdo
liabil difficult forecast assum
settlement payment gener manufactur model
doesnt dramat shift fair valu estim
market valu sever gener drug categori
also seem small estim therefor plan leav
fair valu estim unchang time
meantim feasibl investig could lead
higher-level execut turnov previous would
anticip investig remain
concern still view increas competit price
pressur signific long-term hurdl
gener drug industri -- primari reason no-moat
rate pure-play gener firm
approv near term announc
approv gener version copaxon
lead slightli earlier-than-expect
competit previou forecast doubt teva
appeal previou judgment overturn patent
block gener entrant slightli increas fair
valu estim pull
forward gener launch rais probabl
approv meanwhil weve reduc fair valu estim
teva still place high probabl
momenta mg gener version potenti
contract manufactur issu get resolv
off-set near-term gain also cut
deeper teva expect perform plan revisit
momenta assumpt fair valu estim shortli
increas gener copaxon competit may put
pressur fair valu estim leav
no-moat rate compani place
competit natur seen gener copaxon
support no-moat view gener drug market
given mylan long struggl get version
copaxon approv somewhat surpris oct
announc previous incorpor
probabl approv
version given
momenta previou success version weve
place higher odd approv firm abil get
version across finish line despit good
news hesit translat event
increas odd gener advair still
probabl weight addit still think there
decent probabl teva eventu launch
gener version epipen even though time
complex product remain uncertain
teva momenta version still like oct
although long anticip gener copaxon
sinc weve alreadi anticip gener competit
copaxon event doesnt dramat shift outlook
teva includ recent execut turnov high
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
manufactur facil closur layoffswil littl
off-set recent gener segment competit pressur
earn loss highli profit copaxon
remain near earn far year even though
expect momenta gener copaxon enter
market time still imagin copaxon
remain fairli limit competit product due
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
financi summari forecast
fiscal year end decemb
earn interest tax
return asset
return equiti
valuat summari forecast
equiti
pre-tax debt
weight averag capit
addit estim scenario avail download http //select morningstar com
equival
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
data tabl repres base-cas forecast compani report
currenc begin current year fair valu estim may differ
equiti valu per share shown due time valu money adjust case
probability-weight scenario analysi perform
fiscal year end decemb
good sold
depreci amort report separ
impair charg report separ
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
